1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jinghua Pharmaceutical Group Co., Ltd. Class A

Jinghua Pharmaceutical Group Co., Ltd. Class A

SSZSE:002349
7.42
CNY
+0.07
(+0.95%)
0.36EPS
20.43P/E
5.16BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.22
0.96
0.99
1.05
1.33
1.63
1.42
1.57
1.67
1.93
1.86
1.72
1.78
1.83
Basic EPS, GAAP
0.06
0.07
0.1
0.2
0.21
0.28
-0.48
0.14
0.2
0.26
0.3
0.26
0.27
0.3
Free Cash Flow per Basic Share
-0.19
0.03
-0.17
0.12
-0.43
-0.09
0.04
0.26
0.28
0.36
0.32
0.34
0.39
- -
Dividend per Share
0.03
0.02
0.04
0.04
0.08
0.07
0.07
0.02
0.05
0.07
0.08
0.09
0.08
0.2
Book Value per Share
1.12
1.77
2.42
2.56
2.71
2.73
2.21
2.52
2.68
2.95
3
3.17
3.32
3.4
Tangible Book Value per Share
0.88
1.56
1.53
1.62
1.8
1.77
1.78
2.14
2.3
2.66
2.72
2.89
3.04
3.13
Basic Weighted Avg Shares
600
600
785
840
840
833
814
814
814
814
814
814
819
814
Sales/Revenue/Turnover
733
578
780
881
1,121
1,355
1,157
1,281
1,358
1,573
1,512
1,402
1,460
1,490
Operating Margin (%)
6.92
8.25
11.32
19.98
24.43
23.53
11.66
19.66
14.11
14.97
20.55
18.61
19.48
22.4
Depreciation Expense
25
40
46
60
64
78
81
84
102
110
85
77
81
- -
Net Income, GAAP
36
39
78
165
175
230
-394
111
161
212
248
213
219
247
Effective Tax Rate (%)
5.02
20.48
15.39
14.12
12.22
9.84
- -
56.19
21.76
15.16
16.14
15.63
13.76
13.7
Profit Margin (%)
4.86
6.83
10.01
18.72
15.64
16.95
-34.01
8.66
11.83
13.49
16.38
15.17
15.02
16.6
Working Capital
264
944
787
655
918
745
548
891
992
1,334
1,624
1,519
1,632
1,604
LT Debt
- -
3
1
- -
240
180
220
125
4
1
- -
- -
2
2
Total Equity
742
1,535
2,234
2,303
2,647
2,695
2,148
2,487
2,570
2,624
2,804
2,957
3,149
3,231
Return on Invested Capital (%)
4.8
2.55
3.92
7.12
5.69
8.75
- -
1.08
5.4
8.38
10.71
9.04
9.01
9.4
Return on Capital (%)
4.32
3.38
3.86
6.81
6.26
6.89
- -
7.44
6.9
8.06
8.08
6.18
5.79
6.3
Return on Common Equity (%)
5.5
3.84
4.57
7.89
7.91
10.06
-19.05
5.61
7.4
9.15
10.22
8.46
8.22
9.04

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
3
14
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
830
830
831
Market Capitalization
6,023
6,073
5,161

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,027
2,024
1,967
Cash, Cash Equivalents & STI
1,290
1,244
1,180
Accounts Receivable, Net
322
360
357
Inventories
277
275
274
Total Current Liabilities
395
365
362
Payables & Accruals
- -
- -
- -
ST Debt
2
3
14
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.96%
4.85%
6.5%
Free Cash Flow
-21.42%
9.75%
14.44%
Net Income, GAAP
-16.85%
16.5%
3.12%
Sales/Revenue/Turnover
7.19%
2.96%
4.13%
Total Cash Common Dividend
21.85%
33.48%
-13.64%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
367
353
325
357
1,402
2025
364
368
- -
368
1,460
2026
380
375
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.08
0.04
0.06
0.26
2025
0.08
0.08
- -
0.05
0.27
2026
0.08
0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
- -
-0.03
0.09
2025
- -
0.1
- -
-0.02
0.08
2026
- -
0.12
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jian Cheng
Full Time Employees
1,462
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building A, Guocheng Life Plaza Office Building Nantong JS China 226001
IPO Date
Feb 3, 2010
Website
ntjhzy.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jinghua Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of traditional Chinese patent medicine preparations, chemical active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and Chinese herbal medicines in China. Its product portfolio includes more than 200 types of Chinese and Western medicines, with core products comprising APIs such as Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Propylthiouracil, Piroxicam, Flucytosine, and various traditional Chinese medicine tablets and preparations like Wang's Baochi Pills, Ji Desheng Snake Pills, and Zheng Chai Hu Drink Granules. Jinghua Pharmaceutical maintains GMP certification and complies with Chinese Pharmacopoeia, European Pharmacopoeia, British Pharmacopoeia, and USP standards, with several APIs having obtained Certificate of Suitability and US FDA approvals. Founded in 1957 and headquartered in Nantong, China, the company operates primarily in the Chinese pharmaceutical market, emphasizing both chemical and traditional medicine segments. Recent major developments include Jinghua Pharmaceutical's strategic acquisition plans, notably the pending acquisition of Alpha Pharmaceutical for approximately $165 million, representing a significant expansion of its pharmaceutical production capacity and product offerings. The company has also secured multiple new drug registration certificates and medical device registration approvals in 2024, including for its medical sodium alginate wound dressing, reflecting its ongoing product innovation in both pharmaceuticals and medical devices. Additionally, Jinghua has strengthened its corporate structure through updated industrial and commercial registrations and newly implemented investment and financial management systems to support its expanding operations. These strategic moves signify Jinghua Pharmaceutical's intent to consolidate its market position and broaden its product range in both APIs and proprietary Chinese medicines within China and potentially beyond. This multifaceted pharmaceutical group serves a diverse customer base including hospitals, clinics, pharmaceutical distributors, and traditional medicine markets across China. It is recognized as a government-oriented enterprise with a strong commitment to safe, effective, and stable medicine production, supported by a comprehensive quality assurance framework. Jinghua Pharmaceutical's long-standing industry presence and recent operational enhancements position it as a significant player in China's pharmaceutical landscape.